Table 2.

Primary endpoint: 1-year survival rate (FAS)

	Nivolumab (n = 44)a
Posterior mean of the 1-year survival rate, %	54.4
Posterior mode	54.5
Posterior variance	0.53
90% Bayesian credible intervals	42.27–66.21
Posterior probability that the result of the study exceeds the threshold 1-year survival rate,b %	99.7

^aIncludes one patient who had gliosarcoma

^bThe 1-year survival rate of 34.5% in the JO22506 study (phase 2 study of single-agent bevacizumab in Japanese patients with recurrent glioblastoma) was selected as the threshold 1-year survival rate

FAS full analysis set